IMC-2032

N/A

Report date: 2023/08/11 17:52:23

Base Information

Drug NameIMC-2032
Drug Alias NameIMC-2032
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAging, Prematurebeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmuneCyte Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmuneCyte Inc
Inactive CompaniesN/A
Active IndicationsAging, Prematurebeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A